Table 2 Demographic, clinical and radiological features of the study patients when grouped according to CMB burden
All (N = 127) | CMB = 0 (N = 80) | CMB = 1–4 (N = 27) | CMB ≥ 5 (N = 20) | p | |
|---|---|---|---|---|---|
Gender (Male) | 74 (58.3) | 49 (61.3) | 14 (51.9) | 11 (55) | 0.658 |
Age | 66.57 ± 14.39 | 63.64 ± 15.62 | 63.88 ± 15.52 | 74.08 ± 4.94 | < 0.001 |
Hypertension | 82 (64.6) | 48 (60) | 18 (66.7) | 16 (80) | 0.239 |
Diabetes mellitus | 43 (33.9) | 28 (35) | 9 (33.3) | 6 (30) | 0.913 |
Hyperlipidemia | 45 (35.4) | 28 (62.2) | 10 (22.2) | 7 (15.6) | 0.0981 |
Atrial fibrillation, n(%) | 50 (40) | 29 (37.2) | 8 (29.6) | 13 (65) | 0.035 |
Coronary artery disease, n(%) | 25 (20) | 14 (17.5) | 7 (28) | 4 (20) | 0.519 |
Previous TIA/IS | 26 (20.5) | 19 (23.8) | 1 (3.7) | 6 (30) | 0.043 |
Current antiaggregant/anticoagulant use | 15 (11.8) | 7 (8.8) | 3 (11.1) | 5 (25) | 0.131 |
WMH, n(%) | < 0.001 | ||||
Fazekas Grade 0 | 22 (17.3) | 20 (25) | 2 (7.4) | 0 | |
Fazekas Grade 1 | 32 (25.2) | 23 (23.8) | 9 (33.3) | 0 | |
Fazekas Grade 2 | 38 (29.9) | 23 (23.8) | 9 (33.3) | 6 (30) | |
Fazekas Grade 3 | 35 (27.6) | 14 (17.5) | 7 (25.9) | 14 (70) | |
Neutrophil to lymphocyte ratio | 3.32 ± 2.23 | 3.03 ± 1.72 | 2.9 ± 1.48 | 4.53 ± 3.61 | 0.739 |
Mean platelet volume (fL) | 8.72 ± 1.7 | 8.73 ± 1.68 | 8.68 ± 1.45 | 9.56 ± 2.69 | 0.421 |
Platelet/lymphocyte ratio | 134.74 ± 65.4 | 127.2062 ± 48.431 | 140.1436 ± 77.853 | 138.5925 ± 57.127 | 0.307 |
MPV/platelet ratio | 0.0385 ± 0.015 | 0.0401 ± 0.01624 | 0.0362 ± 0.00932 | 0.0420 ± 0.00872 | 0.406 |
C-reactive protein (mg/dl) | 0.3479 ± 0.324 | 0.3424 ± 0.275 | 0.4633 ± 0.492 | 0.1475 ± 0.058 | 0.147 |